Clinical trials: Heart Failure, Unspecified
Heart Failure With Normal Ejection Fraction, Sleep Apnea
Adherence to ASV Therapy in Heart Failure With Preserved Ejection Fraction Feasibility Study
This study is designed to demonstrate feasibility of study conduct and that acceptable adherence to adaptive servo-ventilation (ASV) therapy can be achieved in recently hospitalized HFpEF patients with moderate to severe sleep…
- Trial name
- CAT-PEF (NCT03195660)
- Testing
- ASV Therapy
- Where
- 4 sites in United States, Germany
- Volunteers
- 6 people
- Sponsor
- ResMed
Chronic Heart Failure
Evaluation of the HeartWare Left Ventricular Assist Device for the Treatment of Advanced Heart Failure
The purpose of this study is to evaluate the safety and effectiveness of the HeartWare® LVAD System in patients listed for cardiac transplantation with refractory, advanced heart failure at risk of death.
- Trial name
- ADVANCE (NCT00751972)
- Testing
- HeartWare® VAS
- Where
- 35 sites in United States
- Volunteers
- 140 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Heart Failure, Myocardial Ischemia
PK and Tolerability of IV and Oral CK-1827452 in Patients With Ischemic Cardiomyopathy and Angina
This study investigates whether symptom-limited exercise capacity in ischemic cardiomyopathy patients with angina is deleteriously affected by treatment with CK-1827452.
- Conditions
- Heart Failure, Myocardial Ischemia, Angina Pectoris
- Trial name
- NCT00682565
- Testing
- CK-1827452 24mg and 6 mg iv infusion, CK-1827452 12.5mg capsule, CK-1827452 48 mg and 11 mg iv infusion
- Where
- 14 sites in Georgia, Russia
- Volunteers
- 94 people
- Sponsor
- Cytokinetics
Heart Failure NYHA Class II, Heart Failure NYHA Class III
A Study to Improve Physician-Youth Communication and Medical Decision Making
The goal of this study is improving patient-centered communication for young people with advanced heart disease.
- Conditions
- Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure NYHA Class IV
- Trial name
- CHATT (NCT05835063)
- Testing
- We Chatt communication tool, Usual/standard care
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- University of Michigan
Heart Failure
CentriMag Ventricular Assist System in Treating Failure-to-Wean From Cardiopulmonary Bypass
The purpose of the study is to evaluate the safety and effectiveness of the CentriMag ventricular assist system to help patients who have experienced heart failure during surgery and cannot be removed from cardiac bypass.
- Trial name
- NCT00819793
- Testing
- CentriMag Ventricular Assist System
- Where
- 14 sites in United States
- Volunteers
- 32 people
- Sponsor
- Abbott Medical Devices
Heart Failure
Torsemide Comparison With Furosemide for Management of Patients With Stable Heart Failure
The study is designed to be a prospective, randomized study is to compare the effectiveness of two standard of care loop diuretics (furosemide versus torsemide) on clinical outcomes among patients currently on a stable dose of…
- Trial name
- TFO (NCT05093621)
- Testing
- Furosemide, Torsemide
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Yale University
Cardiomyopathies, Congestive Heart Failure
Survey of QRS Frequency at Various Left Ventricular Pacing Sites for Cardiac Resynchronization
LV pacing at various sites with recording of ECG and subsequent signal analysis at different sites.
- Trial name
- NCT03253809
- Testing
- Biotronik Vision Guidewire
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- The Cleveland Clinic
Congestive Heart Failure
Evaluation of Cardiac Compass With OptiVol in the Early Detection of Decompensation Events for Heart Failure
The purpose of the PRECEDE-HF study is to collect data to compare patients whose heart failure is managed using Cardiac Compass with OptiVol (which is a tool in the device that records information about the heart that doctors can…
- Trial name
- PRECEDE-HF (NCT00510198)
- Testing
- Cardiac Compass with OptiVol Fluid Status Monitoring, Standard of Care alone (clinical assessment)
- Where
- 33 sites in United States
- Volunteers
- 120 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Heart Failure
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
This study was to determine early and more chronic changes in concentrations of biomarkers related to mechanisms of action (MOA) and effects of sacubitril/valsartan therapy over a period of 12 months, and correlated these…
- Trial name
- PROVE-HF (NCT02887183)
- Testing
- LCZ696 (sacubitril/valsartan)
- Where
- 77 sites in United States
- Volunteers
- 794 people
- Sponsor
- Novartis Pharmaceuticals
Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC), Amyloidosis, Hereditary
ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)
The purpose of this study was to evaluate the safety and efficacy of revusiran (ALN-TTRSC) in patients with transthyretin (TTR) mediated Familial Amyloidotic Cardiomyopathy.
- Conditions
- Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC), Amyloidosis, Hereditary, Amyloid Neuropathies, Familial, Amyloid Neuropathies
- Trial name
- NCT02319005
- Testing
- Revusiran (ALN-TTRSC), Sterile Normal Saline (0.9% NaCl)
- Where
- 61 sites in United States, Belgium and 7 more
- Volunteers
- 206 people
- Sponsor
- Alnylam Pharmaceuticals
Heart Failure, Congestive
Statin Therapy in Heart Failure: Potential Mechanisms of Benefit
The goal of the investigators' study is to further understand the potentially beneficial effects of statin therapy in patients with heart failure.
- Trial name
- NCT00233480
- Testing
- atorvastatin
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of California, Los Angeles
Heart Failure, Heart Failure With Reduced Ejection Fraction
Effectiveness of CRD-740 in Heart Failure
This is a study evaluating the effectiveness of CRD-740 in patients with either Heart Failure with Reduced Ejection Fraction (HFrEF) or Heart Failure with Preserved Ejection Fraction (HFpEF) after 12 weeks of treatment.
- Conditions
- Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction, Cardiovascular Diseases
- Trial name
- CARDINAL-HF (NCT05409183)
- Testing
- CRD-740
- Where
- 34 sites in United States, Canada and 2 more
- Volunteers
- 60 people
- Sponsor
- Cardurion Pharmaceuticals, Inc.
Heart Failure
Study of Renal Denervation in Patients With Heart Failure
Congestive heart failure is a common disorder in which the heart cannot pump enough blood to meet the needs of the rest of the body.
- Trial name
- PRESERVE (NCT01954160)
- Testing
- Symplicity Renal Denervation
- Where
- 12 sites in United States
- Volunteers
- 5 people
- Sponsor
- Adrian Hernandez
Heart Failure
Conduction System Pacing Optimized Therapy
The purpose of the CSPOT study is to determine the best mode of cardiac resynchronization therapy (CRT) pacing for different populations of CRT patients, comparing traditional biventricular or left ventricular pacing (BiV)…
- Trial name
- CSPOT (NCT04905290)
- Testing
- Left ventricular coronary sinus (BiV) configuration, Conduction system pacing-only configuration, Conduction System Pacing Optimized Therapy (CSPOT) configuration
- Where
- 12 sites in United States, Ireland and 2 more
- Volunteers
- 60 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Hypertension, Heart Failure
Pivotal Bioequivalence Study to Qualify Manufacturing Site Transfer for Prazosin Hydrochloride Capsules
Prazosin hydrochloride (HCl) is an oral anti-hypertensive indicated for the treatment of primary and secondary hypertension and heart failure. Pfizer Inc.
- Trial name
- NCT04967443
- Testing
- Prazosin HCl 2mg, Prazosin HCl 1 mg, Prazosin HCl 5 mg
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Pfizer
Heart Failure, Congestive Heart Failure
Daxor - Blood Volume Analysis
The purpose of this study is to better understand blood volume status and whether knowledge of it can change and improve heart failure care.
- Trial name
- NCT04111185
- Testing
- Receive Blood Volume Analysis Guided Treatment
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Duke University
Heart Failure
Surveillance and Alert-based Multiparameter Monitoring to Reduce Worsening Heart Failure Events
The main goal of this study is to use data from the Bodyport Cardiac Scale to help detect of worsening heart failure (HF) early.
- Trial name
- SCALE-HF1 (NCT04882449)
- Testing
- Bodyport Cardiac Scale
- Where
- 8 sites in United States
- Volunteers
- 329 people
- Sponsor
- Bodyport Inc.
Left Sided Heart Failure, Left Ventricular Assist Device
Ventricular Assist Device Anti-Factor Xa (VAD ANTIX) Monitoring Study: a Prospective Randomized Feasibility Trial
This study evaluates two different methods for monitoring a patient's anti-clotting [heparin] therapy after they receive a heart pump implant [left ventricular assist device -LVAD].
- Conditions
- Left Sided Heart Failure, Left Ventricular Assist Device, Anticoagulant Therapy, Gastro Intestinal Bleeding
- Trial name
- VAD-ANTIX (NCT03143569)
- Testing
- aPTT guided heparin management, Anti-factor Xa guided heparin management
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
Heart Failure
Trial Assessing the Effectiveness of Ivabradine Started at Discharge From the Observation Unit
Ivabradine (IVA) has been shown to decrease the risk of hospitalizations for worsening Heart Failure and was associated with a trend towards improved mortality in the SHIFT1 trial.
- Trial name
- OBSERVE-IVA (NCT03168529)
- Testing
- Ivabradine
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Phillip Levy
Heart Failure, Myocardial Ischemia
METhotrexate Therapy Effects in the Physical Capacity of Patients With ISchemic Heart Failure (METIS Trial)
The aim of the study is to evaluate the efficacy of methotrexate to improve physical capacity in patients with symptomatic ischemic heart failure.
- Trial name
- METIS (NCT00759811)
- Testing
- Methotrexate
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Instituto de Cardiologia do Rio Grande do Sul